Back Hepatitis B

Hepatitis B

Boys with Chronic Hepatitis B May Experience HBeAg Seroconversion and Reduced HBV Viral Load at Puberty

Boys with chronic hepatitis B virus (HBV) infection may experience hepatitis B "e" antigen (HBeAg) seroconversion and see a reduction in HBV DNA levels when they reach puberty, according to a study published in the March 2010 issue of Gastroenterology. These findings shed further light on sex differences in the natural history of hepatitis B.

Read more:

Long-term Data Show Telbivudine (Tyzeka) Suppresses HBV Viral Load and Leads to HBeAg Clearance in Chronic Hepatitis B Patients

At the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) this month in Boston, researchers reported 4-year data from the GLOBE study, indicating that the nucleoside analog telbivudine (Tyzeka) continues to provide long-term viral load suppression, ALT normalization, and hepatitis B "e" antigen (HBeAg) seroconversion in chronic hepatitis B patients. Another study showed sustained response up to 2 years after completing telbivudine treatment.alt

Read more:

EASL 2009: Does HBV Viral Load Level Predict Development of Liver Fibrosis?

Two studies presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen looked at the association between HBV DNA level and development of fibrosis, with findings suggesting that the role of HBV viral load differs for hepatitis B "e" antigen (HBeAg) negative and HBeAg positive individuals.


Read more:

AASLD Issues Updated Practice Guidelines for Management of Chronic Hepatitis B

The American Association for the Study of Liver Diseases (AASLD) published a revised version of its "Practice Guidelines for Management of Chronic Hepatitis B" in the September 2009 issue of Hepatology. Key changes are new recommendations for first-line and second-line antiviral therapy, reflecting the latest research on hepatitis B virus (HBV) treatment and the recent approval of tenofovir (Viread) for this indication.

Read more:

Investigational 2-Dose Dynavax Heplisav Hepatitis B Vaccine May Work Better than Standard 3-Dose Energix-B Vaccine

An investigational hepatitis B virus (HBV) vaccine may offer the same degree of protection with 2 doses as the standard Engerix-B vaccine does with 3 doses, according to a study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.

Read more:

Bone Loss and Vitamin D Deficiency Are Common among People with Liver Cirrhosis

People with liver cirrhosis -- a potential outcome of chronic hepatitis B or C -- frequently experience bone loss, or reduced bone mineral density (BMD), and often have low vitamin D levels, according to an Indian study published in the July 28, 2009 issue of World Journal of Gastroenterology.

Read more:

Addition of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis B

As described in a poster presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen, T. Berg and an international team of colleagues conducted Study 106, comparing the efficacy of tenofovir/emtricitabine combination therapy versus tenofovir alone for the treatment of chronic hepatitis B.

Read more:

Should Entecavir (Baraclude) and Tenofovir (Viread) Be First-line Treatment for Chronic Hepatitis B?

At the annual Digestive Disease Week (DDW 2009) meeting this week in Chicago, a panel of experts discussed the prevention and management of antiviral drug resistance in patients receiving long-term treatment for chronic hepatitis B virus (HBV) infection, according to DDW Daily News, the official conference newspaper.

Read more:

Some Individuals Harbor HBV with Adefovir and Tenofovir Resistance Mutations before They Ever Receive Treatment

Several nucleoside/nucleotide drugs have potent activity against hepatitis B virus (HBV), but the virus can rapidly develop resistance, presenting a barrier to long-term treatment success.

Read more: